Anika Therapeutics, Inc.ANIK

Market cap

$371.88M

P/E ratio

	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022
Revenue	65	71	75	106	93	103	113	106	115	130	148	156
Cost of revenue	-	-	-	-	-	-	-	31	29	61	65	63
Gross profit	38	42	52	85	72	79	86	74	86	69	83	94
Research & development	6	5	7	8	9	11	19	18	17	23	27	28
Selling, general & administrative	18	15	13	15	15	18	22	34	35	60	74	85
Goodwill impairment charge	-	-	-	-	-	-	-	-	-	43	-	-
Change in fair value of contingent consideration	-	-	-	-	-	-	-	-	-	-29	-21	-
Total operating expenses	51	52	42	44	45	53	68	84	80	97	80	113
(Loss) income from operations	14	20	33	61	48	51	46	22	34	-28	3	-19
Interest and other income (expense) , net	-182,388	-187,777	-127,186	58,137	0	0	0	1	2	-0	-0	1
(Loss) income before income taxes	14	19,527,421	32	62	48	51	46	23	36	-29	2	-19
Benefit from for income taxes	5	8	12	23	17	18	14	4	9	-5	-2	-4
Net (loss) income	8	12	21	38	31	33	32	19	27	-24	4	-15
Basic (in dollars per share)	0.65	0.89	1.46	2.61	2.06	2.22	2.18	1.3	1.93	-1.69	0.29	-1.02
Diluted (in dollars per share)	0.62	0.82	1.39	2.51	2.01	2.15	2.11	1.27	1.89	-1.69	0.28	-1.02
Net (loss) income	8	12	21	38	31	33	32	19	27	-24	4	-15
Foreign currency translation adjustment	-	-	-	-	-2	-1	3	-1	-0	1	-1	-1
Comprehensive (loss) income	8	12	22	36	29	32	34	18	27	-23	3	-16